Silexion Therapeutics director Amnon Peled resigns
Silexion Therapeutics Corp, a Cayman Islands company with Ordinary Shares and warrants listed on The Nasdaq Stock Market, reported a change in its Board of Directors.
Rhea-AI Filing Summary
Silexion Therapeutics Corp, a Cayman Islands company with Ordinary Shares and warrants listed on The Nasdaq Stock Market, reported a change in its Board of Directors. On July 30, 2026, Professor Amnon Peled notified the Board of his resignation as a director.
His resignation is for personal reasons and will be effective as of August 1, 2026. The company reports that his decision did not arise from any disagreement with Silexion regarding its operations, policies, or practices.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Ordinary Share par value: $0.135 per share
Warrant exercise price: $15,525,00 per share
Resignation notice date: July 30, 2026
+1 more
4 metrics
Ordinary Share par value
$0.135 per share
Par value of Silexion Therapeutics Corp Ordinary Shares listed on Nasdaq
Warrant exercise price
$15,525,00 per share
Exercise price of Nasdaq-listed warrants exercisable for Ordinary Shares
Resignation notice date
July 30, 2026
Date Professor Amnon Peled notified the Board of his resignation
Resignation effective date
August 1, 2026
Effective date of Professor Amnon Peled’s resignation from the Board
Key Terms
Emerging growth company, Warrants exercisable for Ordinary Shares, par value
3 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
par value financial
"Ordinary Shares, par value $0.135 per share"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Silexion Therapeutics (SLXN) report on July 31, 2026?
Silexion Therapeutics reported that Professor Amnon Peled resigned from its Board of Directors. He notified the Board on July 30, 2026, and his resignation, cited as for personal reasons, becomes effective on August 1, 2026, with no disagreement reported over company operations.
When is Professor Amnon Peled’s resignation from Silexion Therapeutics (SLXN) effective?
Professor Amnon Peled’s resignation from Silexion Therapeutics’ Board is effective August 1, 2026. He informed the Board of his decision on July 30, 2026, and the company specifies that his departure is for personal reasons and not due to any disagreement.
Did Professor Amnon Peled leave Silexion Therapeutics (SLXN) because of disagreements with the company?
The company states that Professor Peled’s resignation did not result from any disagreement. It specifically notes there were no disputes regarding Silexion’s operations, policies, or practices, and describes his decision to step down from the Board as being for personal reasons.
Where is Silexion Therapeutics (SLXN) headquartered and what is its contact number?
Silexion Therapeutics is headquartered at 12 Abba Hillel Road, Ramat-Gan, Israel 5250606. The company lists its main telephone contact as +972-3-756-4999, which serves as the registrant’s principal executive office phone number for corporate communications.
What securities of Silexion Therapeutics (SLXN) are registered under Section 12(b)?
Silexion has Ordinary Shares, par value $0.135 per share, and warrants exercisable for Ordinary Shares at a stated exercise price registered under Section 12(b). Both classes are listed on The Nasdaq Stock Market LLC under symbols SLXN and SLXNW, respectively.
AI-generated analysis. How Rhea-AI works. Not financial advice.
